Transforming the treatment of respiratory tract diseases including influenza, RSV and COVID-19
Pneumagen has demonstrated that its engineered mCBM40s bind with high affinity to sialic acid. These engineered mCBM40s have been shown to prevent and treat viral RTIs by masking epithelial cell surface sialic acid receptors present in the respiratory tract, used by several pathogens for entry and infection.
In addition to the mCBM40 family of mCBMs, Pneumagen continues to utilise its GlycoTarge™ platform to develop other mCBM family bacterial glycosidases for use in infectious disease.
Advantages of mCBM40’s over anti-virals and vaccines
Viruses continue to be a threat to human health and a burden on the health services. This burden is fuelled by annual seasonal influenza outbreaks, the emergence of viruses with pandemic potential such as SARS-COV-2 and the development of resistance to current antiviral drugs. This resistance is caused as the virus rapidly mutates rendering the anti-viral drugs and vaccines ineffective.
As Pneumagen’s mCBM40’s target the viral binding site in the respiratory tract, they have the advantage of not being subject to direct viral resistance. Significant time is required to develop a vaccine against a new virus strain and their effectiveness maybe limited, particularly in high-risk groups such as the elderly. By directly preventing the binding and entry of pathogens, CBMs have the advantage of being effective across multiple different viral strains including influenza viruses (IFVs), parainfluenza viruses, certain coronaviruses, including SARS-COV-2, the virus causing COVID-19, enteroviruses and bacteria including Streptococcus pneumoniae.
Our innovative platform GlycoTarge is fundamental to our transformational treatment approach.
Carbohydrate Binding Modules (CBMs): First in class glycan-targeted proteins for the treatment of respiratory tract infections
Pneumagen is using its platform technology, GlycoTarge, to develop novel biologics for the treatment of disease.
Pneumagen’s lead products are based on the carbohydrate-binding module Family 40 domain (CBM40 domain) derived from bacterial sialidases. Pneumagen has engineered oligomers of these monomeric CBM40s by genetically linking copies in tandem, with a trimerisation domain, resulting in multivalent proteins (mCBM40s) with a greatly increased binding affinity for sialic acid (sub-nanomolar).